A Phase II Study on Continuous Infusional Paclitaxel and 5-Fu as First-line Chemotherapy for Patients with Advanced Esophageal Cancer

Gu, Ming; Li, Su-Yi; Huang, Xin-En; Lin, Yan; Cheng, Hong-Yan; Liu, Lin

추천

검색

자료유형: 학술저널

저자정보: Gu, Ming (Department of Oncology, Yancheng Hospital, Medical School of Southeast University) Li, Su-Yi (Department of Oncology, Zhongda Hospital, Medical School of Southeast University) Huang, Xin-En (Department of Chemotherapy, Jiangsu Cancer Hospital & Research Institute) Lin, Yan (Department of Oncology, the Second Affiliated Hospital of Nanjing Medical University) Cheng, Hong-Yan (Department of Oncology, Zhongda Hospital, Medical School of Southeast University) Liu, Lin (Department of Oncology, Zhongda Hospital, Medical School of Southeast University)

저널정보: 아시아태평양암예방학회 Asian Pacific journal of cancer prevention : APJCP Asian Pacific journal of cancer prevention : APJCP 제13권 제11호

발행연도: 2012.1

수록면: 5,587 - 5,591 (5page)

이용수

📌

연구주제

📖

연구배경

🔬

연구방법

🏆

연구결과

초록· 키워드

오류제보하기

Objective: This study was performed to evaluated the efficacy and safety of continuous infusional paclitaxel and 5-Fu as first-line chemotherapy in patients with advanced esophageal squamous cell cancer (ESCC). Methods: A total of 22 patients with advanced esophageal squamous cell cancer with no indications for surgery and radiation therapy, or recurrent patients were enrolled from October 2008 to November 2010. All were treated with PTX 20 $mg/m^2$ was administered through a 16 hours continuous intravenous infusion on days 1 to 3, 8 and 9. DDP 3.75 $mg/m^2$ was given on days 1 to 4 and 8 to 11, continuous infusional 5-FU over 24-hours on days 1 to 5 and 8 to 12 at a dose of 375 $mg/m^2$, and folacin 60 mg orally synchronized with 5-Fu. The treatment was repeated every 21 days for at least two cycles. Results: 22 cases of all enrolled patients could be evaluated for the effect of treatment: 2 cases were CR, 9 cases PR, 5 cases SD and 2 cases PD, giving an overall response rate of 68.2%(15/22). The median time to progression was 7.0 months. The adverse reactions related to chemotherapy were tolerable; the most common toxic effects were marrow depression, alopecia, and fatigue. Conclusion: Low-dose continuous infusional PTX over 16-hours and 5-fu over 24-hours is a promising regimen with good tolerability in treating patients with advanced esophageal squamous cell cancer.

#Paclitaxel #5-Fu #continuous intravenous infusion #esophageal squamous cell cancer #chemotherapy

참고문헌 (0)

참고문헌 신청

참고문헌이 DBpia에서 서비스 중이라면, [참고문헌 신청]을 통해 등록해보세요